NEW YORK – Proteomics firm Nautilus Biotechnology said Friday that it has received notification from the Nasdaq that its common stock bid price has closed below the required minimum of $1.00 per share for the last 30 consecutive business days.

紐約——蛋白質組學公司Nautilus生物技術公司週五表示，已收到納斯達克的通知，稱其普通股出價在過去連續30個交易日中已低於每股1.00美元的最低要求。

In accordance with Nasdaq rules, the company now has 180 calendar days, or until Oct. 28, to regain compliance with the minimum bid price requirement. To do so, Nautilus's stock must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during that period..

根據納斯達克規則，該公司現在有180個日曆日，或直到10月28日，以重新遵守最低出價要求。在此期間，Nautilus的股票必須保持至少10個連續交易日的收盤出價不低於每股1.00美元。

If the company does not regain compliance during this period, it may be eligible for an additional 180-day period during which it can achieve compliance.

如果公司在此期間未能重新遵守規定，它可能有資格獲得額外的180天期限以實現合規。

Nautilus is developing a single-molecule proteome analysis platform but has failed multiple times to hit development timelines and most recently

鸚鵡螺公司正在開發一個單分子蛋白質組分析平臺，但已多次未能按時完成開發計劃，最近一次是

pushed back

推遲

the projected launch of its system to late 2026. In February, the company laid off 16 percent of its staff in an effort to extend its cash runway.

其系統預計推出時間推遲到2026年底。今年2月，該公司裁員16%，以延長其現金週轉時間。